We are live on ! Find out more
LXEO icon

Lexeo Therapeutics
LXEO

69 hedge funds and large institutions have $269M invested in Lexeo Therapeutics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

311% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 9

200% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 5

17% more funds holding

Funds holding: 59 → 69 (+10)

9.32% more ownership

Funds ownership: 80.63% → 89.94% (+9.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

37% less capital invested

Capital invested by funds: $426M → $269M (-$157M)

Holders
69
Holders Change
+10
Holders Change %
+16.95%
% of All Funds
0.99%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
37
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$14.9M
2
BlackRock
BlackRock
New York
+$10M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$7.15M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.42M
5
Verition Fund Management
Verition Fund Management
Connecticut
+$4.24M

Top Sellers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
-$18M
2
AG
Artal Group
Luxembourg
-$9.68M
3
B
Braidwell
Connecticut
-$7.8M
4
NHAS
Novo Holdings A/S
Denmark
-$3.91M
5
LCM
Laurion Capital Management
New York
-$2.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Perceptive Advisors
New York
$1.26M +$1.67M +139,835 New
BFM
27
Boothbay Fund Management
New York
$972K +$1.28M +107,484 New
EAM
28
Exome Asset Management
New York
$797K +$1.05M +88,148 New
Goldman Sachs
29
Goldman Sachs
New York
$694K +$595K +49,898 +186%
Charles Schwab
30
Charles Schwab
California
$577K +$394K +33,013 +107%
PAMP
31
Polar Asset Management Partners
Ontario, Canada
$541K -$65.6K -5,500 -8%
ACM
32
ADAR1 Capital Management
Texas
$517K +$666K +55,866 +4,297%
Wellington Management Group
33
Wellington Management Group
Massachusetts
$469K +$355K +29,791 +135%
Barclays
34
Barclays
United Kingdom
$454K +$370K +31,057 +162%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$434K +$193K +16,177 +51%
Bank of America
36
Bank of America
North Carolina
$351K +$288K +24,134 +165%
Millennium Management
37
Millennium Management
New York
$336K -$4.2K -352 -0.9%
N
38
Nuveen
North Carolina
$326K +$212K +17,757 +97%
Jane Street
39
Jane Street
New York
$323K +$106K +8,918 +33%
PCM
40
Prelude Capital Management
New York
$278K +$366K +30,725 New
Jacobs Levy Equity Management
41
Jacobs Levy Equity Management
New Jersey
$274K +$362K +30,346 New
PP
42
PDT Partners
New York
$241K +$317K +26,608 New
Citigroup
43
Citigroup
New York
$209K +$138K +11,560 +100%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$190K +$92K +7,713 +58%
CC
45
Caxton Corporation
New Jersey
$161K – – –
AllianceBernstein
46
AllianceBernstein
Tennessee
$144K +$62.3K +5,220 +49%
MIM
47
MetLife Investment Management
New Jersey
$129K +$93.1K +7,803 +122%
Mirae Asset Global ETFs Holdings
48
Mirae Asset Global ETFs Holdings
Hong Kong
$116K +$95.3K +7,988 +164%
CF
49
Corebridge Financial
Texas
$114K +$84.6K +7,093 +129%
UBS Group
50
UBS Group
Switzerland
$100K +$95.2K +7,983 +255%
1
2
3

LXEO Hedge Fund Activity: Q3 2024 in Review

69 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q3 2024, worth a combined $269M — down 37% from $426M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LXEO positions and 5 closed out — a net gain of 10 holders — while 37 added to existing stakes and 9 trimmed.

The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $14.9M. The largest seller was Eventide Asset Management, cutting an estimated $18M.

  • 69 institutional investors held Lexeo Therapeutics (LXEO) as of Q3 2024, up from 59 in Q2 2024.
  • Funds reported $269M of Lexeo Therapeutics stock for Q3 2024, down 37% quarter-over-quarter.
  • 15 funds opened new Lexeo Therapeutics positions in Q3 2024 and 5 closed out, a net change of +10 holders.
  • The largest Lexeo Therapeutics buyer in Q3 2024 was Frazier Life Sciences Management, an estimated $14.9M added.
  • The largest Lexeo Therapeutics seller in Q3 2024 was Eventide Asset Management, an estimated $18M sold.

Based on aggregated 13F filings for Q3 2024.